 Home > Medical News > Latest Medical News > Eli Lilly terminates development of psoriasis drug mirikizumab

Eli Lilly terminates development of psoriasis drug mirikizumab

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

turmeric ulcerative colitis

abbvie bioresearch center

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, Eli Lilly said it would abandon the regulatory application for mirikizumab to treat psoriasis, although this IgG4 monoclonal antibody performed better than Novartis’ Cosentyx in last year’s phase 3 trial.

According to Eli Lilly’s latest financial report for the first quarter of 2021, Eli Lilly’s sales increased by 17% and revenue increased by 16%.

However, the most noticeable announcement in this financial report is Eli Lilly's decision to abandon the submission of the psoriasis treatment drug mirikizumab to the regulatory application.

The results of the trial showed that compared with placebo, patients who received mirikizumab met the primary endpoint and all key secondary endpoints in the 16th week.

However, the latest news shows that Eli Lilly does not intend to submit a regulatory application for mirikizumab in the field of psoriasis in any country or region.

However, this decision does not mean that Eli Lilly has completely abandoned the development of mirikizumab, but will focus its attention on ulcerative colitis and Crohn's disease.

Although Stelara has been approved for use in ulcerative colitis, Eli Lilly believes that Stelara can only target IL-23 instead of attacking IL-12 and IL-23 at the same time, so mirikizumab has the potential to surpass the efficacy of Stelara.

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.